Metallo therapeutics for COVID-19. Exploiting metal-based compounds for the discovery of new antiviral drugs. Cirri, D., Pratesi, A., Marzo, T., & Messori, L. Expert Opinion on Drug Discovery, 16(1):39–46, 2021. Publisher: Taylor & Francis![Metallo therapeutics for COVID-19. Exploiting metal-based compounds for the discovery of new antiviral drugs [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Introduction: The COVID-19 pandemic poses an unprecedented challenge for the rapid discovery of drugs against this life-threatening disease. Owing to the peculiar features of the metal centers that are currently used in medicinal chemistry, metallodrugs might offer an excellent opportunity to achieve this goal. Areas covered: Two main strategies for developing metal-based drugs against the SARS-CoV-2 are herein illustrated. Firstly, a few clinically approved metallodrugs could be evaluated in patients according to a ‘drug repurposing’ approach. To this respect, the gold drug auranofin seems a promising candidate, but some other clinically established metal compounds are worthy of a careful evaluation as well. On the other hand, libraries of inorganic compounds, featuring a large chemical diversity, should be screened to identify the most effective molecules. This second strategy might be assisted by a pathway-driven discovery approach arising from a preliminary knowledge of the mode of action, exploitable to inhibit the functional activities of the key viral proteins. Also, attention must be paid to selectivity and toxicity issues. Expert opinion: The medicinal inorganic chemistry community may offer a valuable contribution against COVID-19. The screening of metallodrugs’ libraries can expand the explored ‘chemical space’ and increase the chance of finding effective anti-COVID agents.
@article{cirri_metallo_2021,
title = {Metallo therapeutics for {COVID}-19. {Exploiting} metal-based compounds for the discovery of new antiviral drugs},
volume = {16},
issn = {1746045X},
url = {https://doi.org/10.1080/17460441.2020.1819236},
doi = {10.1080/17460441.2020.1819236},
abstract = {Introduction: The COVID-19 pandemic poses an unprecedented challenge for the rapid discovery of drugs against this life-threatening disease. Owing to the peculiar features of the metal centers that are currently used in medicinal chemistry, metallodrugs might offer an excellent opportunity to achieve this goal. Areas covered: Two main strategies for developing metal-based drugs against the SARS-CoV-2 are herein illustrated. Firstly, a few clinically approved metallodrugs could be evaluated in patients according to a ‘drug repurposing’ approach. To this respect, the gold drug auranofin seems a promising candidate, but some other clinically established metal compounds are worthy of a careful evaluation as well. On the other hand, libraries of inorganic compounds, featuring a large chemical diversity, should be screened to identify the most effective molecules. This second strategy might be assisted by a pathway-driven discovery approach arising from a preliminary knowledge of the mode of action, exploitable to inhibit the functional activities of the key viral proteins. Also, attention must be paid to selectivity and toxicity issues. Expert opinion: The medicinal inorganic chemistry community may offer a valuable contribution against COVID-19. The screening of metallodrugs’ libraries can expand the explored ‘chemical space’ and increase the chance of finding effective anti-COVID agents.},
number = {1},
journal = {Expert Opinion on Drug Discovery},
author = {Cirri, Damiano and Pratesi, Alessandro and Marzo, Tiziano and Messori, Luigi},
year = {2021},
pmid = {32915656},
note = {Publisher: Taylor \& Francis},
keywords = {Auranofin, COVID-19, SARS-CoV-2, drug repurposing, inorganic pharmacology, metal-based drugs},
pages = {39--46},
}
Downloads: 0
{"_id":"uAL8JHLJmrWwgrARR","bibbaseid":"cirri-pratesi-marzo-messori-metallotherapeuticsforcovid19exploitingmetalbasedcompoundsforthediscoveryofnewantiviraldrugs-2021","author_short":["Cirri, D.","Pratesi, A.","Marzo, T.","Messori, L."],"bibdata":{"bibtype":"article","type":"article","title":"Metallo therapeutics for COVID-19. Exploiting metal-based compounds for the discovery of new antiviral drugs","volume":"16","issn":"1746045X","url":"https://doi.org/10.1080/17460441.2020.1819236","doi":"10.1080/17460441.2020.1819236","abstract":"Introduction: The COVID-19 pandemic poses an unprecedented challenge for the rapid discovery of drugs against this life-threatening disease. Owing to the peculiar features of the metal centers that are currently used in medicinal chemistry, metallodrugs might offer an excellent opportunity to achieve this goal. Areas covered: Two main strategies for developing metal-based drugs against the SARS-CoV-2 are herein illustrated. Firstly, a few clinically approved metallodrugs could be evaluated in patients according to a ‘drug repurposing’ approach. To this respect, the gold drug auranofin seems a promising candidate, but some other clinically established metal compounds are worthy of a careful evaluation as well. On the other hand, libraries of inorganic compounds, featuring a large chemical diversity, should be screened to identify the most effective molecules. This second strategy might be assisted by a pathway-driven discovery approach arising from a preliminary knowledge of the mode of action, exploitable to inhibit the functional activities of the key viral proteins. Also, attention must be paid to selectivity and toxicity issues. Expert opinion: The medicinal inorganic chemistry community may offer a valuable contribution against COVID-19. The screening of metallodrugs’ libraries can expand the explored ‘chemical space’ and increase the chance of finding effective anti-COVID agents.","number":"1","journal":"Expert Opinion on Drug Discovery","author":[{"propositions":[],"lastnames":["Cirri"],"firstnames":["Damiano"],"suffixes":[]},{"propositions":[],"lastnames":["Pratesi"],"firstnames":["Alessandro"],"suffixes":[]},{"propositions":[],"lastnames":["Marzo"],"firstnames":["Tiziano"],"suffixes":[]},{"propositions":[],"lastnames":["Messori"],"firstnames":["Luigi"],"suffixes":[]}],"year":"2021","pmid":"32915656","note":"Publisher: Taylor & Francis","keywords":"Auranofin, COVID-19, SARS-CoV-2, drug repurposing, inorganic pharmacology, metal-based drugs","pages":"39–46","bibtex":"@article{cirri_metallo_2021,\n\ttitle = {Metallo therapeutics for {COVID}-19. {Exploiting} metal-based compounds for the discovery of new antiviral drugs},\n\tvolume = {16},\n\tissn = {1746045X},\n\turl = {https://doi.org/10.1080/17460441.2020.1819236},\n\tdoi = {10.1080/17460441.2020.1819236},\n\tabstract = {Introduction: The COVID-19 pandemic poses an unprecedented challenge for the rapid discovery of drugs against this life-threatening disease. Owing to the peculiar features of the metal centers that are currently used in medicinal chemistry, metallodrugs might offer an excellent opportunity to achieve this goal. Areas covered: Two main strategies for developing metal-based drugs against the SARS-CoV-2 are herein illustrated. Firstly, a few clinically approved metallodrugs could be evaluated in patients according to a ‘drug repurposing’ approach. To this respect, the gold drug auranofin seems a promising candidate, but some other clinically established metal compounds are worthy of a careful evaluation as well. On the other hand, libraries of inorganic compounds, featuring a large chemical diversity, should be screened to identify the most effective molecules. This second strategy might be assisted by a pathway-driven discovery approach arising from a preliminary knowledge of the mode of action, exploitable to inhibit the functional activities of the key viral proteins. Also, attention must be paid to selectivity and toxicity issues. Expert opinion: The medicinal inorganic chemistry community may offer a valuable contribution against COVID-19. The screening of metallodrugs’ libraries can expand the explored ‘chemical space’ and increase the chance of finding effective anti-COVID agents.},\n\tnumber = {1},\n\tjournal = {Expert Opinion on Drug Discovery},\n\tauthor = {Cirri, Damiano and Pratesi, Alessandro and Marzo, Tiziano and Messori, Luigi},\n\tyear = {2021},\n\tpmid = {32915656},\n\tnote = {Publisher: Taylor \\& Francis},\n\tkeywords = {Auranofin, COVID-19, SARS-CoV-2, drug repurposing, inorganic pharmacology, metal-based drugs},\n\tpages = {39--46},\n}\n\n\n\n","author_short":["Cirri, D.","Pratesi, A.","Marzo, T.","Messori, L."],"key":"cirri_metallo_2021-1","id":"cirri_metallo_2021-1","bibbaseid":"cirri-pratesi-marzo-messori-metallotherapeuticsforcovid19exploitingmetalbasedcompoundsforthediscoveryofnewantiviraldrugs-2021","role":"author","urls":{"Paper":"https://doi.org/10.1080/17460441.2020.1819236"},"keyword":["Auranofin","COVID-19","SARS-CoV-2","drug repurposing","inorganic pharmacology","metal-based drugs"],"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/FRGBergamini","dataSources":["o2mL7kG99iAQPpNRJ"],"keywords":["auranofin","covid-19","sars-cov-2","drug repurposing","inorganic pharmacology","metal-based drugs"],"search_terms":["metallo","therapeutics","covid","exploiting","metal","based","compounds","discovery","new","antiviral","drugs","cirri","pratesi","marzo","messori"],"title":"Metallo therapeutics for COVID-19. Exploiting metal-based compounds for the discovery of new antiviral drugs","year":2021}